|
|
News Breaks | | | | November 21, 2012 | | 10:20 EDT |  | GSK, AET, VVUS, PFE, OREX, RHHBY, ARNA | VIVUS rallies after Aetna revises obesity drug policy
In a Clinical Policy Bulletin revision dated November 20, 2012, Aetna (AET) specified criteria under which the insurer considers weight reduction medications as "medically necessary" for treatment of obesity. Aetna stated, "For members whose medical policies do not exclude weight reduction medications or services and supplies for or related to weight reduction programs, Aetna covers [the following] drugs under the medical benefit, not the pharmacy benefit." Among the medications that have been approved by the FDA for weight reduction which would be covered under its policy, Aetna listed Qsymia, marketed by VIVUS (VVUS), Belviq from Arena Pharmaceuticals (ARNA), Didrex from Pfizer's (PFE) Pharmacia unit, Roche's (RHHBY) Xenical, and GlaxoSmithKline's (GSK) Alli. Early session strength in shares of VIVUS and Arena has been attributed to Aetna's policy revision, and shares of Orexigen Therapeutics (OREX), which is developing a weight loss treatment that is being considered by the FDA for approval, have also moved higher. In early morning trading, VIVUS advanced $1.58, or 15.27%, to $11.93, Arena gained 20c, or 2.24%, to $9.13 and Orexigen added 30c, or 6.88%, to $4.66. | |
|
News For VVUS;ARNA;OREX;AET;RHHBY;PFE;GSK From The Last 14 Days Check below for free stories on VVUS;ARNA;OREX;AET;RHHBY;PFE;GSK the last two weeks. |
|
|
| June 18, 2013 | | 09:38 EDT |  | PFE | Active equity option families trading on open
Active equity option families trading on open according to Track Data: AAPL NFLX GOOG PFE TSLA MGM | | | 08:37 EDT |  | GSK | Drug companies turn to microchips to test medicines, WSJ reports
 Subscribe for More Information | | | 07:13 EDT | | GSK | Aspen in talks buy GSK's Arixtra, Fraxiparine brands
Subscribe for More Information | | | 07:07 EDT | | GSK | GlaxoSmithKline receives offer for thrombosis brands from Aspen
GlaxoSmithKline said it received an offer for its thrombosis brands and Notre-Dame de Bondeville site from Aspen Global. A period of exclusivity has been agreed with Aspen. The financial terms are confidential at this time, but the offer includes the transfer of the Arixtra and Fraxiparine brands to Aspen, along with the related manufacturing site and the majority of employees at NDB in France and certain dedicated commercial employees, GSK said. "The proposed transaction is aligned to GSK's strategy of focusing on products with the most growth potential and the delivery of its pipeline," the company added. | | | June 17, 2013 | | 16:00 EDT | | PFE | Options Update; June 17, 2013
Subscribe for More Information | | | 08:36 EDT | | PFE | InSite Vision to join Merck, Pfizer patent suit against Mylan
InSite Vision (INSV) announced that it will join Merck (MRK) and Pfizer (PFE) in filing a patent infringement lawsuit against Mylan Pharmaceuticals (MYL). Mylan recently filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking to market a generic version of AzaSite before expiration of the patents covering AzaSite and its use. AzaSite is marketed by Merck in the U.S. On May 26, 2011, InSite and Merck filed a similar patent infringement lawsuit against Sandoz. A trial date for the Sandoz ANDA suit has been set for July 11, 2013. The companies have agreed that Merck will take the lead in prosecuting both lawsuits. Each company will be responsible for their own legal costs, with InSite assuming a monitoring role, the company said. | | | 07:28 EDT |  | PFE | Cambridge Healthtech Institute to host a conference
Subscribe for More Information | | | 07:11 EDT | | VVUS | VIVUS urges stockholders to vote on the GOLD proxy card
VIVUS mailed a letter to stockholders advising them to protect the value of their investment in VIVUS by voting the GOLD proxy card. The letter stated "VIVUS stockholders face an important decision at the upcoming 2013 VIVUS Annual Meeting of Stockholders. Your board and management team have made substantial progress in laying the foundation for Qsymia, and now we are poised to drive future sales by providing broad access to the millions of patients whose lives would benefit from this important therapy. While much progress has already been made, careful and timely execution of the next phase of our retail commercialization plan will be critical to the success of VIVUS. This phase of our retail commercialization plan, after REMS modification, requires a major pharmaceutical company to reach the primary care physicians. As such, we are in discussions with large pharmaceutical companies to explore opportunities as to how we may work together to maximize sales of Qsymia. We strongly believe that electing First Manhattan nominees at the Annual Meeting will jeopardize the progress we are making, and will throw VIVUS into turmoil. At this critical juncture in the company's history, FMC, which owns less than 10% of the company's stock, is trying to seize control of 100% of the VIVUS Board and your company. We strongly urge you not to jeopardize the important progress your Board and management team are making and risk your investment." | | | 06:42 EDT | | AET | Choices provided by health insurance exchanges to vary widely, NY Times says
Subscribe for More Information | | | June 15, 2013 | | 15:26 EDT | | AET | Aetna leaving individual insurance market in California, WSJ says
As the federal health law is set to reshape the insurance market in 2014, Aetna will stop selling health insurance to individual consumers in California at the end of 2013, says the Wall Street Journal. Reference Link | | | | June 14, 2013 | | 16:00 EDT | | PFE | Options Update; June 14, 2013
Subscribe for More Information | | | 08:11 EDT | | ARNA | Arena Pharmaceuticals management to meet with Leerink
Subscribe for More Information | | | 06:45 EDT | | PFE | Zoetis volatility elevated into Pfizer split-off
Subscribe for More Information | | | June 13, 2013 | | 16:00 EDT | | PFE | Options Update; June 13, 2013
Subscribe for More Information | | | 11:02 EDT | | RHHBY | Leerink's major pharma analyst holds an analyst/Industry conference call
Subscribe for More Information | | | 07:32 EDT | | PFE | European League Against Rheumatism to host annual meeting
Subscribe for More Information | | | June 12, 2013 | | 19:54 EDT | | GSK | GlaxoSmithKline investigates bribe claims in China, WSJ says
Subscribe for More Information | | | 16:02 EDT | | PFE | Options Update; June 12, 2013
Subscribe for More Information | | | 13:31 EDT | | PFE | Mylan could be interested in generic assets split from Pfizer, Bloomberg says
| | | 08:28 EDT | | PFE | Teva to pay $1.6B to settle with Pfizer, Nycomed over generic Protonix
Subscribe for More Information | | |
|
|
|
|
|
|
